Cargando…
Development and Validation of a Predictive Model for Metastatic Melanoma Patients Treated with Pembrolizumab Based on Automated Analysis of Whole-Body [(18)F]FDG PET/CT Imaging and Clinical Features
SIMPLE SUMMARY: Blockade of the programmed cell death protein 1 (PD-1) receptor is an established standard-of-care treatment option that significantly improves survival of patients with advanced melanoma. While a smaller proportion of the population can derive a durable remission (even cure), most p...
Autores principales: | Dirks, Ine, Keyaerts, Marleen, Dirven, Iris, Neyns, Bart, Vandemeulebroucke, Jef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452475/ https://www.ncbi.nlm.nih.gov/pubmed/37627111 http://dx.doi.org/10.3390/cancers15164083 |
Ejemplares similares
-
Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
por: Vermeulen, Sim, et al.
Publicado: (2021) -
(18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
por: Wong, Annie, et al.
Publicado: (2020) -
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
por: Lambert, Ine, et al.
Publicado: (2021) -
Pembrolizumab for the treatment of uveal melanoma: A case series
por: Jansen, Yanina Jeanne Leona, et al.
Publicado: (2020) -
Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on (18)F-FDG-PET/CT
por: Amrane, Karim, et al.
Publicado: (2022)